Calliditas aktie rusar efter positiva studieresultat

Nya studiedata för Calliditas njurläkemedel Nefecon fick bolagets aktie att stiga med över 20 procent på måndagsförmiddagen. "Vi tror att datan, baserad på fas III-studiepopulationen, stödjer regulatorisk ansökan om fullständigt godkännande", säger vd:n Renée Aguiar-Lucander.

By Anders Göransson

March 13, 2023 11:37 AM

I fas III-studien undersöks effekten av Nefecon jämfört med placebo hos patienter med njursjukdomen primär IgA-nefropati, IgAN.

Enligt Calliditas uppfyllde studien sitt primära effektmått, en påtaglig statistiskt signifikant skillnad gentemot placebo i uppskattad glomerulär filtrationshastighet. Resultaten uppges även återspegla en ihållande nytta av behandlingen.

1 month free trial

Get access to all content on Life Science Nordic

No commitment or card information required

Try Life Science Nordic now

Already a subscriber? Log In

Applies to personal subscription only.

{{ comments.count === 1 ? '1 comment' : comments.count > 1 ? '{0} comments'.replace('{0}', comments.count) : 'Write a comment' }}

By submitting the comment you accept the terms. See terms

Good comment behavior

Keep a good tone in your comments, avoid personal attacks and posts of marketing character. Apply only link on your comment if it is relevant to the debate.

Be aware that the debates are moderated by the portal's editorial team.

The comment has been created.

Your comment will not be visible until you activate it. In a few moments you will receive an email where you must click on a link to activate your comment.

Yes please, I would like to receive Life Science Nordics newsletter Read cookie and data policy.

Yes please, I would like to receive marketing, offers, surveys, etc. from Life Science Nordic Read cookie and data policy.

{{ window.visitor.corporateClient.name }}

Corporate solution

{{ window.visitor.ipAccess.corporateClient.name }}

{{ window.visitor.corporateClient.name }}

Calliditas aktie rusar efter positiva studieresultat

“Ozempic babies” – myth or reality?

Hacker group claims Chinese bid for stolen Novo data

AstraZeneca scraps late‑stage study – and reports dual successes in lung cancer

Life Science Nordic launches – bringing Nordic life science news under one roof

Lantheus challenges Eli Lilly with FDA-approved Alzheimer’s tracer

Hansa chair: “Too many boards spend far too much time looking inwards”

ZEISS Innovation Summit returns to Berlin

Ensuring Safety and Compliance for IVD Products

100 000 timmar av beprövad tillförlitlighet: KNF:s membranpumpar sätter en ny standard

60 års expertis inom läcksökning: Pfeiffer Vacuum+Fab Solutions firar ett jubileum

From Complex Biology to Faster Decisions: Scalable 3D HCA for NAM-Driven Drug Discovery

QAdvis & Scandinavian CRO are now Aurevia

Experience fast and easy optical inspection

Strengthen your team with Clinical and Regulatory Experts

Clinical and regulatory expertise that delivers results

Medtech Compliance Forum by Aurevia & RAPS

Experienced clinical and regulatory support for a busy autumn

Expanding into the EU market?